Enterprise Therapeutics' ETD001 Shows Promise as Novel Inhaled ENaC Blocker for Cystic Fibrosis Treatment
核心洞察
Enterprise Therapeutics (搜索) published Phase 1 results showing ETD001, a long-acting inhaled epithelial sodium channel (搜索) blocker, was well tolerated in healthy participants at doses higher than those predicted to be therapeutic.
The drug demonstrated a favorable pharmacokinetic profile with slow absorption from the lung and prolonged retention, suggesting extended duration of action for more than 16 hours after a single dose.
Blood potassium levels remained within normal limits at all tested doses, addressing a key safety concern associated with ENaC (搜索) blockade in the kidney.
Enterprise Therapeutics (搜索) has published promising Phase 1 results for ETD001, a novel long-acting inhaled epithelial sodium channel (搜索) (ENaC (搜索)) blocker designed to treat cystic fibrosis (搜索), demonstrating good tolerability and a pharmacokinetic profile consistent with extended lung retention. The peer-reviewed study, published in The Journal of Cystic Fibrosis, represents a significant step forward in developing new therapies for patients with mucus obstruction (搜索) in the lungs.
Phase 1 Trial Design and Safety Profile
The Phase 1 study evaluated the safety, tolerability and pharmacokinetics of ETD001 through single and multiple ascending inhaled doses at levels predicted to be efficacious in humans. Results showed that ETD001 was well tolerated both at single doses and with repeat dosing twice daily for up to 14 days, with doses higher than those predicted to be therapeutic showing good safety profiles.
A critical safety finding was that blood potassium levels remained within normal limits at all doses tested. This addresses a key safety concern associated with ENaC (搜索) blockade in the kidney, where target-mediated ENaC blockade can lead to changes in blood potassium levels.
Distinctive Pharmacokinetic Properties
Unlike earlier inhaled ENaC (搜索) blockers, ETD001 displayed a pharmacokinetic profile consistent with slow absorption from the lung into systemic circulation, suggesting prolonged retention in the lung and potential for extended duration of action. These findings align closely with preclinical data, which demonstrated a favorable safety profile and extended duration of action in the lung for more than 16 hours after a single inhaled dose.
The prolonged lung retention represents a significant advancement over historical inhaled ENaC (搜索) blockers, potentially allowing for less frequent dosing while maintaining therapeutic efficacy.
Addressing Unmet Medical Need in Cystic Fibrosis
Cystic fibrosis (搜索) affects over 100,000 people worldwide, with average life expectancy of around 60 years. The condition is characterized by failed mucociliary clearance and mucus congestion in the lungs, leading to cycles of infection, inflammation and progressive decline in lung function.
"There is an urgent need for new therapies to treat mucus obstruction (搜索) in the lungs of people with CF, and especially those who are genetically unsuited to CFTR modulators," said Dr. Henry Danahay, Head of Biology at Enterprise Therapeutics (搜索) and lead author of the paper. "We are passionate about working towards treatments that will benefit all people with cystic fibrosis (搜索) and are excited to publish these promising results from our Phase 1 trial."
Mechanism of Action and Therapeutic Potential
Inhibiting ENaC (搜索) in the airways offers a potential route to restore airway mucus hydration and drive significant improvements in lung health. The findings from the Phase 1 trial were consistent with preclinical models showing long-lasting improvements in mucociliary clearance, supporting the therapeutic rationale for ENaC blockade in cystic fibrosis (搜索).
Phase 2 Development Program
Enterprise is currently conducting a Phase 2 trial (NCT06478706) investigating whether 28 days of treatment with ETD001 improves lung function in people with cystic fibrosis (搜索). The company expects headline data from this trial in early 2026, which will provide crucial efficacy data to support the drug's therapeutic potential.
The Phase 2 trial represents an important milestone in developing treatments for all people with cystic fibrosis (搜索), particularly those who may not benefit from existing CFTR modulators due to genetic factors.